Bio-Path Holdings, Inc.

Equities

BPTH

US09057N4097

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
2.68 ^USD	+1.71%		-37.53%	-71.06%

Apr. 19	Bio-Path Closes $1.2 Million Share Offering	MT
Apr. 18	Bio-Path Holdings, Inc. Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1B Clinical Trial of Bp1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients	CI

Bio-Path Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 07, 2024 at 04:21 pm EST

Bio-Path Holdings, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 16.08 million compared to USD 13.87 million a year ago. Basic loss per share from continuing operations was USD 33.63 compared to USD 38.12 a year ago.

Diluted loss per share from continuing operations was USD 33.63 compared to USD 38.12 a year ago.

Latest news about Bio-Path Holdings, Inc.

Bio-Path Closes $1.2 Million Share Offering	Apr. 19	MT
Bio-Path Holdings, Inc. Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1B Clinical Trial of Bp1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients	Apr. 18	CI
Bio-Path Holdings, Inc. Expands Global Patent Portfolio	Apr. 15	CI
North American Morning Briefing : Investors on Edge as High-Stakes Jobs Report Awaited	Apr. 05	DJ
Transcript : Bio-Path Holdings, Inc., Q4 2023 Earnings Call, Mar 08, 2024	Mar. 08
North American Morning Briefing : Stock Futures -2-	Mar. 08	DJ
Bio-Path Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients	Jan. 10	CI
Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1B Clinical Trial of Bp1002 in Refractory/Relapsed Acute Myeloid Leukemia	Dec. 14	CI
Transcript : Bio-Path Holdings, Inc., Q3 2023 Earnings Call, Nov 15, 2023	Nov. 15
North American Morning Briefing : Stocks Seen -2-	Nov. 15	DJ
Bio-Path Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Certain Warrants of Bio-Path Holdings, Inc. are subject to a Lock-Up Agreement Ending on 1-NOV-2023.	Oct. 31	CI
Certain Options of Bio-Path Holdings, Inc. are subject to a Lock-Up Agreement Ending on 1-NOV-2023.	Oct. 31	CI
Certain Common Stock of Bio-Path Holdings, Inc. are subject to a Lock-Up Agreement Ending on 1-NOV-2023.	Oct. 31	CI
Transcript : Bio-Path Holdings, Inc. - Special Call	23-10-30
Transcript : Bio-Path Holdings, Inc., Q2 2023 Earnings Call, Aug 15, 2023	23-08-15
North American Morning Briefing : China Angst -2-	23-08-15	DJ
Bio-Path Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Bio-Path Holdings, Inc. Announces Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia	23-08-01	CI
Top Premarket Decliners	23-06-26	MT
Transcript : Bio-Path Holdings, Inc., Q1 2023 Earnings Call, May 12, 2023	23-05-12
North American Morning Briefing : Hopes of Easing -2-	23-05-12	DJ
Bio-Path Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Transcript : Bio-Path Holdings, Inc., Q4 2022 Earnings Call, Mar 31, 2023	23-03-31

Chart Bio-Path Holdings, Inc.

Duration

Period

More charts

Company Profile

Bio-Path Holdings, Inc. is a biotechnology company. The Company is engaged in developing DNAbilize, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the bodyâs enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. Its lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase II study for blood cancers, and BP1001-A, a drug product modification of prexigebersen, is in a Phase I/Ib study for solid tumors. The Companyâs second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. BP1003 is its third liposome delivered antisense drug candidate.

Sector

Biotechnology & Medical Research

Calendar

2024-05-15 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.68 USD

Average target price

40 USD

Spread / Average Target

+1,392.54%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BIO-PATH HOLDINGS, INC.	-71.06%	4.2M
IQVIA HOLDINGS INC.	+1.51%	42.75B
MODERNA, INC.	+8.57%	41.34B
LONZA GROUP AG	+49.22%	41.61B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research